Munich Reinsurance Co Stock Corp in Munich Invests $2.14 Million in Waters Corporation $WAT

Munich Reinsurance Co Stock Corp in Munich purchased a new stake in shares of Waters Corporation (NYSE:WAT) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,151 shares of the medical instruments supplier’s stock, valued at approximately $2,144,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Mondrian Investment Partners LTD acquired a new position in Waters during the third quarter worth about $1,397,000. Vanguard Group Inc. raised its position in Waters by 3.3% in the third quarter. Vanguard Group Inc. now owns 7,656,891 shares of the medical instruments supplier’s stock worth $2,295,612,000 after acquiring an additional 246,128 shares in the last quarter. Alberta Investment Management Corp acquired a new stake in Waters in the 3rd quarter valued at about $4,677,000. Veritas Asset Management LLP acquired a new stake in Waters in the 3rd quarter valued at about $175,320,000. Finally, Deroy & Devereaux Private Investment Counsel Inc. boosted its position in shares of Waters by 41.9% during the 3rd quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 13,802 shares of the medical instruments supplier’s stock valued at $4,138,000 after purchasing an additional 4,077 shares in the last quarter. 94.01% of the stock is currently owned by institutional investors.

Waters Stock Down 4.2%

Waters stock opened at $302.44 on Friday. Waters Corporation has a twelve month low of $275.05 and a twelve month high of $414.15. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.27 and a current ratio of 1.73. The firm has a market cap of $29.67 billion, a PE ratio of 28.08, a P/E/G ratio of 2.08 and a beta of 1.20. The firm’s 50 day moving average price is $361.44 and its two-hundred day moving average price is $351.27.

Waters (NYSE:WAT) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The company had revenue of $932.36 million during the quarter, compared to analyst estimates of $928.17 million. During the same quarter last year, the business posted $4.10 EPS. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. On average, research analysts predict that Waters Corporation will post 12.86 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on WAT. UBS Group lowered their price objective on shares of Waters from $395.00 to $370.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Guggenheim restated a “buy” rating and set a $440.00 target price on shares of Waters in a report on Tuesday, February 10th. Weiss Ratings restated a “hold (c)” rating on shares of Waters in a research report on Wednesday, January 21st. Robert W. Baird set a $363.00 price target on Waters in a report on Tuesday, February 10th. Finally, HSBC assumed coverage on Waters in a research report on Tuesday, January 27th. They set a “buy” rating and a $460.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $393.84.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.